Bakers Union and FELRA Health and Welfare Fund

Annual Review
January – December 2023

March 11, 2024

Optum Rx®

Today's Topics

1. Key Discussion Topics
2. Performance Summary
3. Trend
4. Top Disease States
5. Rebates
6. Outcomes
   - Clinical Outcomes
   - Vigilant Outcomes
7. Drug Pipeline

Your OptumRx Team

Paul Marcus
VP, Client Management
Labor & Trust

Holly Agoney
Strategic Account Executive
Labor & Trust

Caroline Atwood
Director, Client Management
Labor & Trust

Autumn Leblanc
Pharmacy Account Manager
Labor & Trust

Fabian Gonzales
Pharmacy Service Specialist
Labor & Trust

Current Plan Design

- Deductible, Ben Max, MOOP, Copays

Plan 1 (group BFWRX):	
Deductible:	This plan has no deductible.
Benefit Maximum:	$2,000 per year for Growth Hormones medications only
Max out of Pocket:	$2,850 Individual / $5,700 Family

Plan 2 (group BFWRX2) & Plan 3 (group BFWRX3):	
Deductible:	This plan has no deductible.
Benefit Maximum:	$2,000 per year for Growth Hormones medications only
Max out of Pocket:	$1,850 Individual / $3,700 Family

Co-pays

Plan 1 (group BFWRX) & Plan 2 (group BFWRX2):			
Retail		Mail	
*Generic:	$10	*Generic:	$20
*Brand:	$15	*Brand:	$30
*NP Brand:	$30	*NP Brand:	$60
*Specialty:	Run trial claim for co-pay	*Specialty:	N/A

Plan 3 (group BFWRX3):	
Retail / Mail	
*Generic:	5% ($5 min.)
*Brand:	15% ($15 min.)
*NP Brand:	25% ($25 min.)
*Specialty:	Run trial claim for co-pay

- **Effective 7/1/19**
  - Diabetes Program
  - Comprehensive Ums
  - Vigilant Program
  - RxOTC Program
- **Effective 8/1/2020**
  - Orphan Drug Program
- **Effective 3/1/2021**
  - Opioid Mgmt – tighter refill window & UMs
- **Effective 7/1/2021**
  - Premium Formulary
  - Mandatory Mail (MSS)
- **Effective 1/1/2022**
  - Split-fill/Smart-fill
- **Effective 3/1/2022**
  - CCAA/VCS
- **Effective 5/15/23**
  - Price Edge

Key Discussion Topics

- Per Member Per Month (PMPM) trend = 43.4% Specialty trend = 201.9%
- Specialty represents 1% of claims

- Top 5 disease states accounted for 73% of total plan paid
  - Top traditional disease state: Diabetes
  - Top specialty disease state: Inflammatory Conditions

- Rebates – Jan – Dec 2023
  - Estimated - $201,400

- Clinical Outcomes savings
  - **UM (PA, ST, QL)** – Jan – Dec 2023
    - Savings = $111,400
  - **Vigilant** – Jan – Dec 2023
    - Savings = $20,251

Key Statistics

Key Statistics – Overall Performance Summary

573
Avg. eligible members

Key statistics with benchmark comparison

Benchmark comparison 1: LABOR AND TRUST

Benchmark comparison 2: COMMERCIAL

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 43.4%, compared to the benchmark trend of 12.6%
- Member Paid Share changed by -27.5% period over period, compared to the benchmark of -8.7%

				LABOR AND TRUST		COMMERCIAL	
Key statistics	**Curr**	**Prev**	**Percent change**	**Curr**	**Percent change**	**Curr**	**Percent change**
Average age	44.3	43.2	2.4%	37.0	0.1%	36.8	0.2%
Plan paid PMPM	$176.21	$122.92	43.4%	$128.49	12.6%	$135.88	15.8%
Plan paid per Rx	$170.62	$115.41	47.8%	$176.82	12.3%	$170.10	16.7%
Rxs PMPM	1.033	1.065	-3.0%	0.727	0.3%	0.799	-0.8%
Average days supply	30.8	29.4	4.7%	40.2	0.9%	39.8	2.7%
Days supply PMPM	31.8	31.3	1.5%	29.2	1.3%	31.8	1.9%
Member paid share	6.5%	8.9%	-27.5%	7.7%	-8.7%	10.8%	-8.1%
Member paid per Rx	$11.78	$11.29	4.4%	$14.78	1.7%	$20.52	6.1%
Generic dispensing rate	83.9%	82.2%	2.1%	86.9%	1.6%	86.0%	1.6%
GDR-without Vaccines	86.3%	86.0%	0.4%	88.2%	0.0%	88.1%	-0.1%
Home delivery rate	6.5%	5.0%	30.4%	7.5%	-2.0%	5.1%	3.4%
Retail 90 rate	1.9%	1.4%	31.1%	17.8%	0.9%	20.4%	4.9%
Percent of specialty plan paid	41.1%	19.5%	110.6%	45.7%	-0.2%	50.3%	-0.4%

Total Rxs

CURRENT
7,100

PREVIOUS
7,906

PERCENT CHANGE
-10.2%

Total plan paid

CURRENT
$1,211,426

PREVIOUS
$912,440

PERCENT CHANGE
32.8%

Utilizers

CURRENT
426

PREVIOUS
462

PERCENT CHANGE
-7.8%

Specialty Key Statistics

Key statistics with benchmark comparison

Comparing metrics to benchmarks help showcase areas of focus.

Benchmark comparison 1: LABOR AND TRUST

Benchmark comparison 2: COMMERCIAL

- Client trend was 201.9%, compared to the benchmark trend of 12.4%
- Member Paid Share changed by -57.0% period over period, compared to the benchmark of -17.4%

				LABOR AND TRUST		COMMERCIAL	
Key statistics	**Curr**	**Prev**	**Percent change**	**Curr**	**Percent change**	**Curr**	**Percent change**
Plan Paid PMPM	$72.47	$24.00	201.9%	$58.73	12.4%	$68.38	15.3%
Plan paid per Rx	$6,824.84	$4,454.70	53.2%	$8,141.53	5.6%	$7,585.96	6.1%
Rxs PMPM	0.011	0.005	97.0%	0.007	6.4%	0.009	8.6%
Average days supply	32.5	27.6	17.6%	31.9	1.3%	31.1	1.3%
Days supply PMPM	0.3	0.1	131.8%	0.2	7.9%	0.3	10.0%
Member paid share	2.0%	4.7%	-57.0%	4.0%	-17.4%	5.2%	-16.7%
Member paid per Rx	$141.95	$221.80	-36.0%	$342.99	-13.6%	$414.56	-12.6%
Generic dispensing rate	0.0%	0.0%	0.0%	7.8%	0.1%	9.0%	-2.1%
Home delivery rate	4.1%	5.0%	-17.8%	3.5%	7.5%	3.0%	0.9%
Retail 90 rate	4.1%	0.0%	0.0%	4.8%	2.8%	4.3%	5.4%

Total Rxs

CURRENT
73

PREVIOUS
40

PERCENT CHANGE
82.5%

Total plan paid

CURRENT
$498,213

PREVIOUS
$178,188

PERCENT CHANGE
179.6%

Utilizers

CURRENT
8

PREVIOUS
7

PERCENT CHANGE
14.3%

Trend Summary

Trend Summary

Trend

Plan paid PMPM has increased 43.4% over the previous period driven primarily by cost in traditional and utilization for specialty.

Specialty represents 1.0% of claims.

▲ 43.4%
Total trend
+30.7% over benchmark

▲ 4.9%
Traditional trend
-8% under benchmark

▲ 201.9%
Specialty trend
+189.5% over benchmark

Optum Rx®

Top Disease States
&
Top 20 Drugs

TRADITIONAL SPECIALTY

Top Disease States

Top 5 disease states account for 73% of total Plan Paid

- Inflammatory Conditions accounts for 28.0% of total plan paid, with trend driven by Utilization. DUPIXENT was the top drug
- Diabetes accounts for 26.8% of total plan paid, with trend driven by Drug Mix. JARDIANCE was the top drug

Sort by: Plan Paid

Disease State	PMPM	Trend	Top driver
Inflammatory Conditions ▲	$49.42	105.9%	Utilization
Diabetes ▲	$47.25	40.4%	Drug Mix
Oncology ▲	$17.53	4,529.4%	Drug Mix
Cardiovascular ▲	$8.72	7.4%	Utilization
Asthma / COPD ▼	$6.46	-49.3%	Cost
All other ▲	$46.84	6.4%	

Top 20 Drugs by Plan Cost

All meds are Brands except indicated with a "G" for generic

Specialty

Rank: Cu	Pv	Bench	Drug name	Therapy class	Utlzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	Trend components: % Trend	Top driver	% Top driver
1	1	6	DUPIXENT	Chronic Inflammatory Disease	4	43	27.7	$149,335	$3,472.92	$21.72	$11.57	$3.16	87.7%	Utlzn	80.0%
2	2	1	HUMIRA PEN	Chronic Inflammatory Disease	1	13	28.0	$92,679	$7,129.14	$13.48	$10.14	$8.31	32.9%	Utlzn	17.0%
3	-	91	KISQALI	Oncology	1	6	28.0	$87,787	$14,631.10	$12.77	$0.00	$0.25	-	-	-
4	-	8	SKYRIZI PEN	Chronic Inflammatory Disease	1	4	43.0	$81,374	$20,343.62	$11.84	$0.00	$2.88	-	-	-
5	7	4	JARDIANCE	SGLT-2 Inhibitors & Combos	9	62	38.7	$43,653	$704.08	$6.35	$3.44	$3.73	84.7%	Utlzn	76.3%
6	-	394	TRIPTODUR	LHRH/GNRH Agonist/Antagonists	1	2	168.0	$39,542	$19,770.81	$5.75	$0.00	$0.04	-	-	-
7	16	2	OZEMPIC	GLP-1 Receptor Agonists	7	23	50.4	$34,956	$1,519.84	$5.08	$1.62	$5.84	213.3%	Utlzn	198.2%
8	52	7	MOUNJARO	GLP-1 Receptor Agonists	8	34	30.0	$34,902	$1,026.53	$5.08	$0.50	$2.91	906.1%	Utlzn	883.3%
9	-	29	IBRANCE	Oncology	1	2	28.0	$31,090	$15,545.22	$4.52	$0.00	$0.77	-	-	-
10	4	5	TRULICITY	GLP-1 Receptor Agonists	5	33	28.2	$28,844	$874.06	$4.20	$3.74	$3.19	12.2%	Cost	7.7%
11	29	11	FARXIGA	SGLT-2 Inhibitors & Combos	5	39	30.0	$21,103	$541.11	$3.07	$0.99	$1.96	211.2%	Utlzn	200.8%
12	6	55	VICTOZA	GLP-1 Receptor Agonists	2	13	46.2	$20,902	$1,607.82	$3.04	$3.53	$0.40	-13.9%	Utlzn	-16.9%
13	3	259	STRIBILD	HIV-Multiclass Combo	1	5	30.0	$20,264	$4,052.82	$2.95	$5.93	$0.07	-50.3%	Utlzn	-55.0%
14	5	10	BIKTARVY	HIV-Multiclass Combo	1	5	30.0	$16,805	$3,361.03	$2.44	$3.58	$2.38	-31.8%	Utlzn	-32.5%
15	13	25	ENTRESTO	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	16	48.8	$16,141	$1,008.79	$2.35	$1.90	$0.90	23.6%	Utlzn	17.0%
16	10	28	JANUMET	DPP-4 Inhibitors & Combos	3	24	35.0	$14,480	$603.34	$2.11	$2.37	$0.80	-11.0%	Utlzn	-16.0%
17	12	16	LANTUS SOLOSTAR	Insulin	10	35	37.9	$12,882	$368.05	$1.87	$2.01	$1.42	-6.9%	Cost	-15.3%
18	18	14	JANUVIA	DPP-4 Inhibitors & Combos	3	25	30.0	$12,662	$506.49	$1.84	$1.47	$1.68	25.1%	Utlzn	22.7%
19	36	23	HUMALOG KWIKPEN	Insulin	6	27	26.4	$12,098	$448.07	$1.76	$0.80	$1.05	119.6%	Utlzn	121.9%
20	24	9	ELIQUIS	Oral Anticoagulants	4	21	30.0	$11,064	$526.85	$1.61	$1.12	$2.44	43.4%	Utlzn	33.9%
Total					47	432	34.5	$782,564	$1,811.49	$113.83	$54.72	$44.17	108.0%		53.9%
Plan Total					426	7,100	30.8	$1,211,426	$170.62	$176.21	$122.92	$128.49	43.4%		28.5%

Diabetes meds (9)

10 out of the top 20 have moved up in rank

Rebates

Rebate Performance Summary

Bakers Union and FELRA Health and Welfare Fund
Outcomes date range: Jan - Dec 2023
Benchmark: LABOR AND TRUST

Current rebate value: $29.29 PMPM

16.6%
Rebate impact

Rebate impact on Plan Paid PMPM

Managing drug spend to a lowest net cost PMPM is achieved through adoption of high performing formulary strategies and driving to lowest net cost products when clinically appropriate. Bakers Union and FELRA Health and Welfare Fund's members adherence to the formulary has earned an offset on PMPM costs, yielding a net plan paid PMPM of $146.92, versus plan paid PMPM of $176.21.

Net financial PMPM performance

	Drug cost	Member Paid	Plan Paid	Rebates	Net plan paid
Traditional	$114.38	$10.66	$103.74	$20.17	$83.57
Specialty	$73.97	$1.51	$72.47	$9.12	$63.35
Total	$188.36	$12.17	$176.21	$29.29	$146.92

Total estimated rebate yield for reporting period: **$201.4K**

Rebate Performance by Disease State

Disease	Drug cost PMPM	Member paid PMPM	Plan paid PMPM	Rebates PMPM	Net plan paid PMPM	Rebate offset
Diabetes	$49.45	$2.20	$47.25	$11.78	$35.47	24.9%
Inflammatory Conditions	$50.91	$1.49	$49.42	$8.00	$41.43	16.2%
Asthma / COPD	$6.82	$0.37	$6.46	$2.23	$4.23	34.5%
Cardiovascular	$10.75	$2.04	$8.72	$1.42	$7.30	16.3%
Diabetic Supplies	$2.98	$0.16	$2.82	$1.12	$1.70	39.8%
Blood Clot Prevention/Stroke Prevention	$3.37	$0.16	$3.21	$0.95	$2.26	29.5%
Oncology	$17.57	$0.04	$17.53	$0.94	$16.59	5.3%
HIV	$6.36	$0.32	$6.05	$0.34	$5.70	5.7%
Gastrointestinal, Misc	$1.14	$0.06	$1.07	$0.33	$0.74	30.7%
Overactive Bladder / Incontinence	$1.10	$0.06	$1.05	$0.27	$0.78	25.7%
Endocrine And Metabolic	$5.98	$0.02	$5.97	$0.26	$5.70	4.4%
Male And Female Hormone Replacement	$1.04	$0.09	$0.95	$0.24	$0.70	25.7%
Ophthalmic Agents	$1.14	$0.12	$1.02	$0.22	$0.80	21.8%
Glaucoma	$1.24	$0.10	$1.14	$0.19	$0.95	17.1%
Contraception	$1.32	$0.03	$1.28	$0.19	$1.09	15.2%
Weight Loss	$1.14	$0.02	$1.13	$0.19	$0.94	16.5%
Kidney Disease	$1.05	$0.03	$1.02	$0.17	$0.85	16.7%
Depression	$2.46	$0.59	$1.87	$0.07	$1.80	4.0%
Migraine/Pain Relief	$0.73	$0.11	$0.62	$0.07	$0.55	11.7%
Antibiotics	$1.42	$0.31	$1.12	$0.07	$1.04	6.5%
Cholesterol Lowering Agents	$4.22	$1.21	$3.01	$0.06	$2.95	1.9%
Neurologic	$0.13	$0.02	$0.11	$0.05	$0.06	45.3%
ADHD & Narcolepsy	$0.03	$0.00	$0.03	$0.02	$0.00	84.6%
Anti-Inflammatory (Steroids)	$0.11	$0.07	$0.04	$0.02	$0.01	65.1%
Severe Allergic Reaction	$0.14	$0.00	$0.14	$0.02	$0.11	18.0%
Antipsychotics	$0.48	$0.03	$0.45	$0.02	$0.42	5.2%
Misc Skin Condition	$1.55	$0.19	$1.36	$0.02	$1.33	1.7%

Clinical Outcomes

UM Outcomes

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Dec 2023

Utilization management savings: $16.20 PMPM

Your program savings: **$111.4K**

Ensuring patients meet appropriate clinical criteria when initiating medication therapy not only helps to ensure that the patient is being treated safely according to guidelines, but also drives significant savings for both Bakers Union and FELRA Health and Welfare Fund and for members. Bakers Union and FELRA Health and Welfare Fund has realized over $111.4K in savings. Based on a study by OptumRx, leveraging UM strategies that drive members to appropriate and often lower cost medications for treatment can save a member up to $620 annually in out of pocket copayments.



Prior authorization

PMPM SAVINGS
$6.35

NUMBER OF MEMBERS IMPACTED
38

NUMBER OF INTERVENTIONS
46

Quantity limits

PMPM SAVINGS
$5.34

NUMBER OF MEMBERS IMPACTED
10

NUMBER OF INTERVENTIONS
11

Step therapy

PMPM SAVINGS
$4.51

NUMBER OF MEMBERS IMPACTED
75

NUMBER OF INTERVENTIONS
91

QL savings is based only on Maximum Daily Dose edits.

OptumRx®

Vigilant Outcomes

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Dec 2023

Total program savings: $2.95 PMPM

Vigilant Drug Outcomes – Cost Avoidance

By leveraging the Vigilant Drug Program, Bakers Union and FELRA Health and Welfare Fund has:

- Avoided $20.3K in pharmacy spend
- Switched 5 claims to lower cost alternatives
- 6 claims were abandoned

$2.95

Total PMPM savings

TOTAL PLAN PAID SAVINGS

$20,251

TOTAL PROGRAM SAVINGS

1.7%

TOTAL MEMBERS IMPACTED

11

Savings by Vigilant Drug List

Sort by: Members impacted Plan paid PMPM savings

Vigilant drug list	PMPM savings	Members impacted	Interventions
High Cost Generics	$1.38	6	6
Clinical Duplicates	$0.29	3	3
High Cost Brands with Generics	$1.28	2	2

Clinical Opportunity
Specialty Standard

Optum Rx Specialty Standards

Clients want benefit-focused specialty cost management strategies that enhance clinical solutions

62% of late-stage pipeline drugs are for high-cost specialty medications[1]

50 medications account for 80% of total specialty spend[2]

66% of 2021 specialty trend is due to increased utilization[3]

Optum Rx Specialty Standards

- Optimizes the benefit with a specialty focus
- Lowers specialty spend
- Complements existing specialty offerings

1. Optum Rx drug pipeline insights. 2. Optum Rx 2022 internal book of business data. 3. Pharmaceutical Strategies Group; 2022 State of Specialty Spend and Trend Report.

Optum Rx Specialty Standards

Modernize the pharmacy benefit and infuse several specialty-focused strategies that are integrated and synergistic to aggressively reduce specialty spend and increase clinical rigor

Specialty expert reviews on highly complex specialty medications

New specialty precision system edits optimize fills and reduce waste

New specialty tiering design to incentivize members to lower cost alternatives

UM optimization

Oversupply stockpiling

Specialty expert review

Dose optimization

Split fill

$0 specialty generics tier (optional)

Product modeling and analysis based on Optum Rx internal book of business data

Optum Rx Specialty Standards

Provide clients a customized specialty management approach with strategic solutions to reduce costs and integrate modernized benefit strategies

Core Benefit Strategies

- Dispense as Written (DAW) 1 and 2
- Premium formulary
- Optum exclusive specialty

Specialty Standards

- UM optimization
- Specialty expert review
- Split Fill
- Oversupply stockpiling
- Dose optimization
- $0 specialty generics tier (optional)

Complementary Specialty Benefit Programs

- Copay Card Solutions
- Review My Care
- Polypharmacy Value Management
- Critical Drug Affordability

Optum Rx Specialty Standards

Specialty Standards opportunity bulk analysis

All savings projections and case counts are based on claims for commercial clients from 2/1/2023 - 1/31/2024

**Savings and case counts represent annual values with the exception of Split Fill which does not allow for annualization*

			UM Optimization		Dispensing Optimization savings	Oversupply Stockpiling Edit savings	Split Fill		
Carrier ID	Account ID	Average membership	*Case count*	*Savings*	*Assumes 50% saving on plan spend for Cosentyx single packs*	*Using Pop Diagnostics Oversupply Specialty metric*	*Savings**	*Total savings*	*Total saving PMPM*
CTR000260	280-118	390	4	$ 8,166.04	$ -	$ -	$ -	**$ 8,166.04**	**$ 1.75**
CTR000260	250-118	143	2	$ 4,083.02	$ -	$ -	$ -	**$ 4,083.02**	**$ 2.38**
CTR000260	250-68	33	0	$ -	$ -	$ -	$ -	**$ -**	**$ -**
CTR000260	250-BFC	3	0	$ -	$ -	$ -	$ -	**$ -**	**$ -**
								$ 12,249.05	annual savings
								$ 3,600.00	fee charges annually
								$ 8,649.05	**net savings**

Fee charges: $0.50pmpm

$3,600 is based on 600 lives

Savings/Charges are estimated

Optum Rx®

Drug Pipeline

Selected generic launches in 2024

****Fund has Utilization in Drugs in Red****

1Q:2024

- **Neupro** (rotigotine): Parkinson's disease; restless legs syndrome
- **Tasigna** (nilotinib)†: Chronic myeloid leukemia **$1.2B**
- **Emflaza** (deflazacort)†: Duchenne muscular dystrophy

2Q:2024

- **Victoza** (liraglutide): Diabetes **$3.7B**
- **Isentress** (raltegravir)†: HIV-1 infection

3Q:2024

- **Sprycel** (dasatinib)†: Leukemia **$2.1B**
- **Oxtellar XR** (oxcarbazepine): Seizures

4Q:2024

- **Qsymia** (phentermine/topiramate)†: Weight management

2022 US Sales

Blockbuster drug
(>$1B in annual U.S. sales)

† Generic has 180-days of exclusivity
HIV = Human Immunodeficiency Virus

Appendix

Trend Components

Total trend: 43.4%

Benchmark comparison: LABOR AND TRUST

- Bakers Union and FELRA Health and Welfare Fund's overall trend of 43.4% was 30.7% higher than benchmark
- Specialty spend influenced the trend contributing 90.9% (46.1% higher than benchmark)
- Traditional trend contributed 9.1% (46.1% lower than benchmark)



Traditional trend: 4.9%

Benchmark comparison: LABOR AND TRUST

- Traditional trend contributed 9.1% to the overall trend (43.4%)
- Traditional accounts for 58.9% of overall total plan paid and was down from 80.5% in the prior period



Specialty trend: 201.9%

Benchmark comparison: LABOR AND TRUST

- Specialty trend contributed 90.9% to the overall trend (43.4%)
- Specialty accounts for 41.1% of overall total plan paid and was up from 19.5% in the prior period



Top 20 traditional

All meds are Brands

Rank													Trend components		
Cu	Pv	Bench	Drug name	Therapy class	Utlzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Trend	Top driver	% Top driver
1	5	2	JARDIANCE ★	SGLT-2 Inhibitors & Combos	9	62	38.7	$43,653	$704.08	$6.35	$3.44	$3.73	84.7%	Utlzn	76.3%
2	13	1	OZEMPIC ★	GLP-1 Receptor Agonists	7	23	50.4	$34,956	$1,519.84	$5.08	$1.62	$5.84	213.3%	Utlzn	198.2%
3	48	4	MOUNJARO ★	GLP-1 Receptor Agonists	8	34	30.0	$34,902	$1,026.53	$5.08	$0.50	$2.91	906.1%	Utlzn	883.3%
4	2	3	TRULICITY ★	GLP-1 Receptor Agonists	5	33	28.2	$28,844	$874.06	$4.20	$3.74	$3.19	12.2%	Cost	7.7%
5	26	7	FARXIGA ★	SGLT-2 Inhibitors & Combos	5	39	30.0	$21,103	$541.11	$3.07	$0.99	$1.96	211.2%	Utlzn	200.8%
6	4	28	VICTOZA ★	GLP-1 Receptor Agonists	2	13	46.2	$20,902	$1,607.82	$3.04	$3.53	$0.40	-13.9%	Utlzn	-16.9%
7	1	132	STRIBILD	HIV-Multiclass Combo	1	5	30.0	$20,264	$4,052.82	$2.95	$5.93	$0.07	-50.3%	Utlzn	-55.0%
8	3	6	BIKTARVY	HIV-Multiclass Combo	1	5	30.0	$16,805	$3,361.03	$2.44	$3.58	$2.38	-31.8%	Utlzn	-32.5%
9	11	14	ENTRESTO	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	16	48.8	$16,141	$1,008.79	$2.35	$1.90	$0.90	23.6%	Utlzn	17.0%
10	8	16	JANUMET ★	DPP-4 Inhibitors & Combos	3	24	35.0	$14,480	$603.34	$2.11	$2.37	$0.80	-11.0%	Utlzn	-16.0%
11	10	9	LANTUS SOLOSTAR	Insulin ★	10	35	37.9	$12,882	$368.05	$1.87	$2.01	$1.42	-6.9%	Cost	-15.3%
12	15	8	JANUVIA ★	DPP-4 Inhibitors & Combos	3	25	30.0	$12,662	$506.49	$1.84	$1.47	$1.68	25.1%	Utlzn	22.7%
13	33	12	HUMALOG KWIKPEN ★	Insulin	6	27	26.4	$12,098	$448.07	$1.76	$0.80	$1.05	119.6%	Utlzn	121.9%
14	21	5	ELIQUIS	Oral Anticoagulants	4	21	30.0	$11,064	$526.85	$1.61	$1.12	$2.44	43.4%	Utlzn	33.9%
15	30	11	XARELTO	Oral Anticoagulants	2	8	75.0	$9,798	$1,224.76	$1.43	$0.89	$1.14	60.8%	Utlzn	54.2%
16	18	772	HUMALOG MIX 50/ 50 KWIKPEN	Insulin ★	1	4	90.0	$9,612	$2,402.94	$1.40	$1.29	$0.01	8.0%	Utlzn	8.0%
17	20	78	BYDUREON BCISE	GLP-1 Receptor Agonists ★	1	12	28.5	$9,297	$774.78	$1.35	$1.21	$0.14	11.6%	Utlzn	8.0%
18	23	42	DEXCOM G6 SENSOR ★	Diabetes Monitoring and Testing Supplies	4	11	73.6	$9,196	$835.96	$1.34	$1.05	$0.29	27.7%	Utlzn	21.5%
19	24	69	TRESIBA FLEXTOUCH ★	Insulin	2	18	19.2	$8,733	$485.19	$1.27	$1.04	$0.15	21.8%	Cost	21.7%
20	12	83	NOVOLOG FLEXPEN ★	Insulin	5	15	34.7	$8,617	$574.46	$1.25	$1.75	$0.12	-28.5%	Utlzn	-35.5%
Total					43	430	36.3	$356,009	$827.93	$51.78	$40.24	$30.61	28.7%		34.8%
Plan Total					426	7,027	30.7	$713,213	$101.50	$103.74	$98.92	$69.75	4.9%		7.4%

★ Diabetes meds (15)

13 out of the top 20 have moved up in rank

Top 20 specialty

All meds are Brands except indicated with a “G” for generic

Rank													Trend components		
Cu	Pv	Bench	Drug name	Therapy class	Utlzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Trend	Top driver	% Top driver
1	1	3	DUPIXENT	Chronic Inflammatory Disease	4	43	27.7	$149,335	$3,472.92	$21.72	$11.57	$3.16	87.7%	Utlzn	80.0%
2	2	1	HUMIRA PEN	Chronic Inflammatory Disease	1	13	28.0	$92,679	$7,129.14	$13.48	$10.14	$8.31	32.9%	Utlzn	17.0%
3	-	43	KISQALI	Oncology	1	6	28.0	$87,787	$14,631.10	$12.77	$0.00	$0.25	-	-	-
4	-	4	SKYRIZI PEN	Chronic Inflammatory Disease	1	4	43.0	$81,374	$20,343.62	$11.84	$0.00	$2.88	-	-	-
5	-	189	TRIPTODUR	LHRH/GNRH Agonist/Antagonists	1	2	168.0	$39,542	$19,770.81	$5.75	$0.00	$0.04	-	-	-
6	-	13	IBRANCE	Oncology	1	2	28.0	$31,090	$15,545.22	$4.52	$0.00	$0.77	-	-	-
7	4	10	OTEZLA	Chronic Inflammatory Disease	1	2	30.0	$9,465	$4,732.70	$1.38	$0.53	$1.15	159.3%	Cost	159.3%
8	3	5	TALTZ	Chronic Inflammatory Disease	1	1	28.0	$6,940	$6,940.24	$1.01	$1.76	$1.91	-42.5%	Utlzn	-46.0%
Total					8	73	32.5	$498,213	$6,824.84	$72.47	$24.00	$19.19	201.9%		131.8%
Plan Total					8	73	32.5	$498,213	$6,824.84	$72.47	$24.00	$58.73	201.9%		131.8%

5 out of the top 8 are for Chronic Inflammatory Disease

4 out of the top 8 have moved up in rank

OptumRx®